Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Bicycle Therapeutics Plc's Business Segments
Bicycle Therapeutics Plc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Single reportable segment
Total Revenue
$ 1
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Single reportable segment100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single reportable segment | $ 1 | 100% |
Description of Bicycle Therapeutics Plc
Bicycle Therapeutics Plc is a clinical-stage biotechnology company that focuses on developing a unique class of small molecule drugs known as bicyclic peptides. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.
The technology used by Bicycle Therapeutics is based on the discoveries made by Nobel Prize laureates Sir Gregory Winter and Sir David Lane. Bicyclic peptides are a type of constrained peptide that consist of two loops, called the wheels, joined by a fixed central core, called the frame. This structure confers stability and high affinity for specific molecular targets, making them superior to conventional peptides.
The main advantage of bicyclic peptides is their ability to combine the best characteristics of both small molecules and large biological drugs. Due to their unique structure, they can penetrate cell membranes and are highly selective in binding to disease-associated targets. This enables them to potentially target a wide range of diseases, including oncology, immunology, and respiratory disorders.
Bicycle Therapeutics has developed a proprietary technology platform called Bicycles, which allows for the rapid and efficient creation of bicyclic peptides with desired properties. This platform combines computational modeling, chemical synthesis, and high-throughput screening to generate libraries of diverse bicyclic peptides. They then use a screening process to identify candidates with high potency and specificity against the target of interest.
The company has a pipeline of product candidates, including both internal candidates and collaborations with pharmaceutical partners. Some of their lead candidates include BT1718, BT5528, and BT8009. BT1718 is being developed for the treatment of solid tumors, BT5528 for the treatment of HER2-positive cancers, and BT8009 for the treatment of chronic obstructive pulmonary disease (COPD) and other respiratory diseases.
In addition to its own research and development efforts, Bicycle Therapeutics has also established collaborations with several pharmaceutical companies, including AstraZeneca, Genentech, and Oxurion. These collaborations provide additional resources and expertise to advance the development and commercialization of their product candidates.
Bicycle Therapeutics went public in May 2019, listing its shares on the NASDAQ Global Market under the ticker symbol BCYC. The company has raised significant funding through its initial public offering (IPO) and private financing rounds to support its research and development activities.
Overall, Bicycle Therapeutics Plc is at the forefront of developing novel therapeutics using its proprietary bicyclic peptide technology. With a diverse pipeline and collaborations with leading pharmaceutical companies, the company is well-positioned to advance its drug candidates and potentially make a significant impact in the field of precision medicine.
The technology used by Bicycle Therapeutics is based on the discoveries made by Nobel Prize laureates Sir Gregory Winter and Sir David Lane. Bicyclic peptides are a type of constrained peptide that consist of two loops, called the wheels, joined by a fixed central core, called the frame. This structure confers stability and high affinity for specific molecular targets, making them superior to conventional peptides.
The main advantage of bicyclic peptides is their ability to combine the best characteristics of both small molecules and large biological drugs. Due to their unique structure, they can penetrate cell membranes and are highly selective in binding to disease-associated targets. This enables them to potentially target a wide range of diseases, including oncology, immunology, and respiratory disorders.
Bicycle Therapeutics has developed a proprietary technology platform called Bicycles, which allows for the rapid and efficient creation of bicyclic peptides with desired properties. This platform combines computational modeling, chemical synthesis, and high-throughput screening to generate libraries of diverse bicyclic peptides. They then use a screening process to identify candidates with high potency and specificity against the target of interest.
The company has a pipeline of product candidates, including both internal candidates and collaborations with pharmaceutical partners. Some of their lead candidates include BT1718, BT5528, and BT8009. BT1718 is being developed for the treatment of solid tumors, BT5528 for the treatment of HER2-positive cancers, and BT8009 for the treatment of chronic obstructive pulmonary disease (COPD) and other respiratory diseases.
In addition to its own research and development efforts, Bicycle Therapeutics has also established collaborations with several pharmaceutical companies, including AstraZeneca, Genentech, and Oxurion. These collaborations provide additional resources and expertise to advance the development and commercialization of their product candidates.
Bicycle Therapeutics went public in May 2019, listing its shares on the NASDAQ Global Market under the ticker symbol BCYC. The company has raised significant funding through its initial public offering (IPO) and private financing rounds to support its research and development activities.
Overall, Bicycle Therapeutics Plc is at the forefront of developing novel therapeutics using its proprietary bicyclic peptide technology. With a diverse pipeline and collaborations with leading pharmaceutical companies, the company is well-positioned to advance its drug candidates and potentially make a significant impact in the field of precision medicine.
Bicycle Therapeutics Plc is a biotechnology company that specializes in developing innovative therapeutics utilizing its proprietary Bicycle technology platform. This platform is based on small peptide-like structures called Bicycles,which are designed to target and modulate specific biological pathways, particularly in the areas of oncology, neurology, and other disease indications. Below, Ive outlined the key segments, products, and services that Bicycle Therapeutics offers.
1. Therapeutic Segments
a. Oncology
Bicycle Therapeutics focuses significantly on developing Bicycles for cancer treatment. The oncology segment includes:
- Targeted Therapeutics: Bicycles are designed to selectively target cancer cells, minimizing damage to healthy tissues. These products can deliver payloads that directly kill cancer cells or modulate their behavior.
- Combination Therapies: Development of Bicycles that can be administered in combination with existing therapies to enhance effectiveness or overcome resistance.
b. Neurology
The company is also exploring the application of its technologies in neurological diseases, focusing on:
- Neurodegenerative Diseases: Bicycles that can cross the blood-brain barrier and selectively target neuroinflammation or other pathological processes in diseases such as Alzheimers or Parkinsons.
- Neurological Disorders: Utilizing Bicycles to modulate receptors or pathways that are disrupted in conditions such as multiple sclerosis or epilepsy.
c. Rare Diseases
Bicycle Therapeutics is leveraging its platform to address rare and genetic diseases, focusing on creating targeted therapies for conditions currently lacking effective treatments.
Products
a. Lead Product Candidates
Bicycle Therapeutics has several lead product candidates in various stages of preclinical and clinical development:
- BT5528: An antibody-drug conjugate (ADC) candidate designed to target and kill cancer cells expressing specific biomarkers. This product merges the targeting ability of Bicycles with potent cytotoxic agents.
- BT7455: A candidate designed for the treatment of solid tumors. This product focuses on leveraging dual modes of action to improve efficacy.
- Bicycle Toxicity Modulator: A therapeutic designed to mitigate the side effects of chemotherapy by protecting healthy cells while targeting cancerous ones.
b. Collaborations and Partnerships
Bicycle Therapeutics has entered into collaborations with other biotechnology and pharmaceutical companies to co-develop product candidates. These partnerships may involve sharing technology, resources, and expertise to foster innovation and expedite developmental timelines.
Services
a. Research and Development Services
The company provides comprehensive R&D services to industry partners, including:
- Custom Bicycle Development: Utilizing its technology to design custom Bicycle-based therapeutics for specific client needs in various therapeutic areas.
- Preclinical Testing: Conducting preclinical studies to assess the efficacy and safety of customized Bicycles before advancing to clinical trials.
- Analytical Services: Offering analytical support for characterizing Bicycle constructs to ensure consistent quality and performance.
b. Licensing Agreements
Bicycle Therapeutics may engage in licensing agreements, allowing third parties to utilize its technology platform. This includes:
- License of Bicycle Technology: Companies can license the platform to develop their own therapeutics using Bicycles tailored to their unique applications.
- Joint Development Programs: Collaborations that involve co-development of Bicycle-based therapeutics, sharing both risks and potential rewards.
Market Applications
The potential applications of Bicycle Therapeutics span multiple sectors, including:
- Pharmaceuticals: Development of small-molecule therapeutics that can be marketed toward oncologists and neurologists.
- Biologics: Creation of new classes of biologic drugs that can provide targeted therapy for challenging diseases.
- Diagnostics: Research into using Bicycles as diagnostic tools for identifying specific disease markers.
Conclusion
Bicycle Therapeutics Plc operates with a robust and versatile approach in the biotechnology sector. With its specialized segments in oncology, neurology, and rare diseases, and the innovative Bicycle technology platform, the company is positioned to advance therapeutic options with improved precision and efficacy. The continuous development of product candidates, alongside collaborative efforts and research services, indicates a strong commitment to addressing unmet medical needs across various diseases.
1. Therapeutic Segments
a. Oncology
Bicycle Therapeutics focuses significantly on developing Bicycles for cancer treatment. The oncology segment includes:
- Targeted Therapeutics: Bicycles are designed to selectively target cancer cells, minimizing damage to healthy tissues. These products can deliver payloads that directly kill cancer cells or modulate their behavior.
- Combination Therapies: Development of Bicycles that can be administered in combination with existing therapies to enhance effectiveness or overcome resistance.
b. Neurology
The company is also exploring the application of its technologies in neurological diseases, focusing on:
- Neurodegenerative Diseases: Bicycles that can cross the blood-brain barrier and selectively target neuroinflammation or other pathological processes in diseases such as Alzheimers or Parkinsons.
- Neurological Disorders: Utilizing Bicycles to modulate receptors or pathways that are disrupted in conditions such as multiple sclerosis or epilepsy.
c. Rare Diseases
Bicycle Therapeutics is leveraging its platform to address rare and genetic diseases, focusing on creating targeted therapies for conditions currently lacking effective treatments.
Products
a. Lead Product Candidates
Bicycle Therapeutics has several lead product candidates in various stages of preclinical and clinical development:
- BT5528: An antibody-drug conjugate (ADC) candidate designed to target and kill cancer cells expressing specific biomarkers. This product merges the targeting ability of Bicycles with potent cytotoxic agents.
- BT7455: A candidate designed for the treatment of solid tumors. This product focuses on leveraging dual modes of action to improve efficacy.
- Bicycle Toxicity Modulator: A therapeutic designed to mitigate the side effects of chemotherapy by protecting healthy cells while targeting cancerous ones.
b. Collaborations and Partnerships
Bicycle Therapeutics has entered into collaborations with other biotechnology and pharmaceutical companies to co-develop product candidates. These partnerships may involve sharing technology, resources, and expertise to foster innovation and expedite developmental timelines.
Services
a. Research and Development Services
The company provides comprehensive R&D services to industry partners, including:
- Custom Bicycle Development: Utilizing its technology to design custom Bicycle-based therapeutics for specific client needs in various therapeutic areas.
- Preclinical Testing: Conducting preclinical studies to assess the efficacy and safety of customized Bicycles before advancing to clinical trials.
- Analytical Services: Offering analytical support for characterizing Bicycle constructs to ensure consistent quality and performance.
b. Licensing Agreements
Bicycle Therapeutics may engage in licensing agreements, allowing third parties to utilize its technology platform. This includes:
- License of Bicycle Technology: Companies can license the platform to develop their own therapeutics using Bicycles tailored to their unique applications.
- Joint Development Programs: Collaborations that involve co-development of Bicycle-based therapeutics, sharing both risks and potential rewards.
Market Applications
The potential applications of Bicycle Therapeutics span multiple sectors, including:
- Pharmaceuticals: Development of small-molecule therapeutics that can be marketed toward oncologists and neurologists.
- Biologics: Creation of new classes of biologic drugs that can provide targeted therapy for challenging diseases.
- Diagnostics: Research into using Bicycles as diagnostic tools for identifying specific disease markers.
Conclusion
Bicycle Therapeutics Plc operates with a robust and versatile approach in the biotechnology sector. With its specialized segments in oncology, neurology, and rare diseases, and the innovative Bicycle technology platform, the company is positioned to advance therapeutic options with improved precision and efficacy. The continuous development of product candidates, alongside collaborative efforts and research services, indicates a strong commitment to addressing unmet medical needs across various diseases.